Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced ovarian cancer with positive BRCA1 or BRCA2 status~* Failed at least one prior chemotherapy~* In investigators opinion, no curative standard therapy exists~* Measurable disease~Exclusion Criteria:~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- KU-0059436 (AZD2281) 100 mg BID (Type: EXPERIMENTAL): None
- KU-0059436 (AZD2281) 400 mg BID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).